Skip to main content

Animations

MJFF Publications

2741 - 2750 of 8808 Results
Title
Year
  • Year
  • 2022
  • 2005
  • 2022
  • 2025
  • 2024
  • 2008
  • 2011
  • 2009
  • 2023
  • 2020
  • Summary Details
    OPEN
    Title: Brain-restricted mTOR inhibition with binary pharmacology
    Journal Name: Nature
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1038/s41586-022-05213-y
    Citation Count: 60
  • Summary Details
    OPEN
    Title: Parkin-deficient mice are not more sensitive to 6-hydroxydopamine or methamphetamine neurotoxicity
    Journal Name: BMC Neuroscience
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1186/1471-2202-6-71
    Citation Count: 66
  • Summary Details
    OPEN
    Title: Use of Glycolysis‐Enhancing Drugs and Risk of Parkinson's Disease
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1002/mds.29184
    Citation Count: 23
  • Summary Details
    OPEN
    Title: A cerebrospinal fluid synaptic protein biomarker for prediction of cognitive resilience versus decline in Alzheimer’s disease
    Journal Name: Nature Medicine
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd, cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1038/s41591-025-03565-2
    Citation Count: 19
  • Summary Details
    OPEN
    Title: Rapid iPSC inclusionopathy models shed light on formation, consequence, and molecular subtype of α-synuclein inclusions
    Journal Name: Neuron
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by, cc-by
    DOI - Digital Object Identifier: 10.1016/j.neuron.2024.06.002
    Citation Count: 12
  • Summary Details
    OPEN
    Title: JNK2 and JNK3 combined are essential for apoptosis in dopamine neurons of the substantia nigra, but are not required for axon degeneration
    Journal Name: Journal of Neurochemistry
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1111/j.1471-4159.2008.05713.x
    Citation Count: 79
  • Summary Details
    OPEN
    Title: Regulation of Physiologic Actions of LRRK2: Focus on Autophagy
    Journal Name: Neurodegenerative Diseases
    Publisher: S. Karger AG
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1159/000332599
    Citation Count: 39
  • Summary Details
    OPEN
    Title: α-Synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity
    Journal Name: Nature Genetics
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1038/ng.300
    Best OA location URL: http://doi.org/10.1038/ng.300
    Citation Count: 527
  • Summary Details
    OPEN
    Title: From policy to practice: Lessons learned from an open science funding initiative
    Journal Name: PLOS Computational Biology
    Publisher: Public Library of Science (PLoS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1371/journal.pcbi.1011626
    Citation Count: 3
  • Summary Details
    OPEN
    Title: Structure of LRRK2 in Parkinson’s disease and model for microtubule interaction
    Journal Name: Nature
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1038/s41586-020-2673-2
    Citation Count: 203
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.